ARS Pharmaceuticals, Inc (SPRY) — Cash Flow Reinvestment Rate
ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Reinvestment Rate of 2.43x as of December 2024, reinvesting $102.06 Million (capex $302.00K plus investments $-101.76 Million) from operating cash flow of $42.00 Million. Explore ARS Pharmaceuticals, Inc (SPRY) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
ARS Pharmaceuticals, Inc Cash Flow Reinvestment Rate (2020–2024)
Historical reinvestment intensity for ARS Pharmaceuticals, Inc across 2 annual periods. Also explore SPRY current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for ARS Pharmaceuticals, Inc (2020–2024)
Year-by-year capital reinvestment analysis for ARS Pharmaceuticals, Inc. For live market cap and broader valuation context, see ARS Pharmaceuticals, Inc stock valuation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 7.87x | $106.66 Million | $13.55 Million | $563.00K | ▲ +7688.0% |
| 2020 | 0.10x | $917.00K | $9.07 Million | $917.00K | — |